Arriving with lofty expectations, Eli Lilly’s Mounjaro (tirzepatide) got its call-up to the big leagues on Friday, with the FDA green-lighting the type 2 diabetes and...

A clinical trial for an Alzheimer’s disease drug approved in China that would otherwise have supported a potential FDA submission has stopped. Impacted by “multip...

Amgen is using a musical theme in its new “Double Take” campaign, which aims to help people with psoriatic arthritis dance to diagnosis. Amgen, which sells two bl...

Bad news for Aurobindo Pharma. Just two months after the generics maker closed up shop at its Aurolife Pharma unit in New Jersey, the company’s oral manufacturing fac...

Despite an ongoing strategic review that might alter Sandoz’s future, the Novartis generics engine keeps churning out new products. Sandoz has launched the first ...

That was fast. Just a month after mRNA giant Moderna unveiled a CFO switch, its new finance chief is out the door because his former employer disclosed an internal ac...

A win in patent court in Europe last October was a pleasant surprise for Bayer, giving its heart drug Xarelto an additional two years of exclusivity—all the way to 20...

Pfizer is channeling the large windfall it’s made from COVID-19 products into dealmaking. Six months after partnering up with Biohaven Pharma on its migraine drug, Pf...

Emergent BioSolutions' COVID-19 vaccine manufacturing woes were well documented in 2021, but a new congressional probe found that the company's problems went much fur...

Bristol Myers Squibb has launched two education campaigns and an annual awareness day for the condition its new heart drug Camzyos treats, with branded consumer ads o...